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Expression and purification of the central domain from vitronectin 
Alexander C. Thurman, Nancy A. Horn, Cynthia B. Peterson 
Abstract 
Vitronectin is a key circulatory glycoprotein, exhibiting interactions with other proteins that regulate wound 
healing, cellular immunity, angiogenesis, coagulation, and fibrinolysis. Vitronectin structure/function depend on 
its localization within the circulation (fluid phase vs. vasculature). The conversion of vitronectin from a 
solution-phase (monomeric) to matrix-phase (oligomeric) form has been proposed to occur via intermolecular 
~-sheet propagation mediated by a ~-propeller region within the central domain (~200 amino acids). In the 
present study, the vitronectin central domain was expressed as a small ubiquitin-related modifier (SUMO) 
fusion protein and purified via diethylaminoethyl (DEAE) and metal chelate (Ni) affinity chromatography. 
Cleavage of the SUMO fusion and purification of the central domain were successfully achieved. However, the 
purified central domain has exhibitied substantial self-aggregative properties that were unmitigated by the 
presence of the SUMO fusion. Thus, while the central domain was successfully isolated, its tendency for self-
aggregation limits its biochemical applications. 
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Introduction 
Vitronectin is a circulatory glycoprotein of established significance, having been implicated in such processes 
as wound healing, cellular immunity, angiogenesis, coagulation, and fibrinolysis. The structure and function of 
vitronectin are location-dependent: Soluble vitronectin monomers exist in circulation, insoluble oligomers in 
association with the extracellular matrix (ECM) of the vasculature. Soluble (monomeric) vitronectin has 
exhibited the capacity to bind several partners, including heparin,I-3 plasminogen activator inhibitor-l 
(PAI_l),4-8 other proteases such as thrombin and urokinase-type plasminogen activator (uPA),9 serpin-protease 
complexes,9-11 and complement proteins,12-14 whereas tissue-associated (oligomeric) vitronectin has been shown 
to interact with the ECM I5 and numerous cell surface receptors, including the uPA receptor (uPAR)16-18 and the 
Uy integrin receptor subc1ass. 19-28 Vitronectin also promotes cell adhesion/migration in fibroblasts, endothelial 
cells, megakaryocytes, platelets, and certain cancer cell lines29 and functions in organogenesis and neural 
development. 30,31 
Vitronectin mediates its most clinically relevant effects via interactions with PAl-I. Binding of PAI-l to 
vitronectin stabilizes the active (inhibitory) conformation of the enzyme and significantly increases its half-
life?2,33 Vitronectin/PAI-l interactions have been implicated in fibrotic lung disease,34 kidney disease/5 liver 
fibrosis,36 atherosclerosis,37 and angiogenesis,38-40 and human alleles corresponding to increased P AI-l 
expression are directly correlated with tumor severity and incidence of myocardial infarction/metabolic 
syndrome.41 -43 Conversion of vitronectin from a solution-phase to a matrix-phase protein is also hypothesized to 
occur via interactions with PAl-I. Subsequent conformational changes in vitronectin are suggested to expose a 
~-propeller region in the central domain - homologous to the four-bladed ~-propeller fold present in another 
circulatory protein, hemopexin44,45 - that induces oligomerization. Such p-propeller domains frequently 
participate in protein-protein interactions,46,47 thus supporting the proposed model for vitronectin self-
association. 
In order to address the hypothesis that the self-association of vitronectin into a matrix-associated oligomeric 
form occurs via intermolecular p-sheet propagation, the vitronectin central domain (VNCD) will be expressed 
in isolation and tested for associative behavior. The mutagenesis and cloning of DNA corresponding to VNCD 
has already been accomplished in the laboratory. The goals for the present research will be to: 1. Optimize 
VNCD expression and purification; and 2. Use high-performance liquid chromatography (HPLC) to evaluate 
purification of this domain. 
MaterialslMethods 
Expression_ The VNCD DNA sequence was inserted into the Champion pET SUMO Expression System (Invitrogen, see Fig. 1) and 
expressed in Rosetta 2(DE3)pLysS Competent Cells (Novagen). Rosetta cell constructs were grown in Terrific broth as 5% (50mL) 
seed cultures and incubated for ~ 16 hours at 30°C. Seed cultures were subsequently transferred to larger flasks (2.8L Fernbach flasks, 
lL TB) and incubated with orbital shaking (300rpm, New Brunswick) at 20°C. When an OD (A600) of ~4 was established, media was 
brought to 1% (w/v) glucose and 2mM IPTG to induce VNCD-SUMO fusion expression, and incubation was continued for ~ 16 hours 
with orbital shaking (300rpm) at 15°C. The final 00 (A600) of the cell cultures was ~6. Cell paste was harvested by centrifugation at 
~ 16000g for 15 minutes at 4°C. 
Cell Lysis. Approximately 90 grams of wet cell paste were suspended in 600mL of 2M urea, 0.02M Na2HP04, 1 % (v/v) Tween 80, 
pH 8.0 buffer containing 3 dissolved Complete Protease Inhibitor Cocktail Tablets (Roche). The suspension was sonicated on ice 
(with stirring) for 30 minutes (1 minute pulse, 30 second rest cycle). Following sonication, the lysate was centrifuged for 20 minutes at 
~16000g (9500 rpm) at 4°C. The supernatant was decanted and collected, and 5 grams of Celpure PIOOO (Advanced Minerals) per 
100mL of lysate were added. The clarified lysate was filtered using a Buchner apparatus with a 0.451lm nylon membrane (MSI) and a 
glass fiber prefilter (Pall) pre-coated with a I cm layer of Celpure PI 000. 
DEAE Chromatography. A 1.5cm x 6cm OEAE Sepharose Fast Flow column (GE Healthcare) was washed and equilibrated with 
2M urea, 0.02M NazHP04, pH 8.0 buffer at 4°C. The filtered/clarified lysate was loaded using a peristaltic pump at a flow rate of 
2 
ImLimin. The column was washed with 2M urea, 0.02M Na2HP04, pH 8.0 buffer until the absorbance profile - monitored with an 
inline UV detector (Pharmacia) - returned to baseline. The column was developed and product eluted with a 400mL linear gradient 
from 2M urea, 0.02M Na2HP04, pH 8.0 to 2M urea, 0.02M Na2HP04, I M NaCi, pH 8.0 at 3mLlmin. Fractions from the dominant 
eluting peak were collected, pooled (see Fig 2.), and analyzed by SDS-PAGE and western blotting. 
Metal Chelate (Ni) Affinity Chromatography I. A l.5cm x 8cm Chelating Sepharose Fast Flow column (GE Healthcare) was 
charged with 0.1 M NiS04. The column was then washed with 10 column volumes of water followed by 10 column volumes of 2M 
urea, 0.02M Na2HP04, 0.3M NaCl, 0.005M imidazole, pH 8.0 buffer at 4°C. The DEAE column pool (320mL) was loaded at a flow 
rate of 3mLlmin and washed with 2M urea, 0.02M Na2HP04, 0.3M NaCl, 0.005M imidazole, pH 8.0 buffer until the absorbance 
returned to baseline. The column was developed with a linear gradient from 2M urea, 0.02M Na2HP04, 0.3M NaCl, 0.005M 
imidazole, pH 8.0 to 2M urea, 0.02M Na2HP04, 0.3M NaCl, 0.3M imidazole, pH 8.0. 10mL fractions were collected, analyzed by 
SDS-PAGE and western blotting, and pooled accordingly (see Fig. 3). 
SUMO Cleavage. 30mL of proteolysis solution was prepared by combining 19.96mL metal chelate affinity eluate (-2Img VNCD-
SUMO fusion protein), 400 units (40IlL) SUMO Protease 1 (Life Sensors), 400llL 150mM DTT solution (2mM DTT in 30mL), and 
9.6mL DI H20. This solution was incubated at 30°C for I hour and subsequently transferred to 4°C for overnight incubation (-12 
hours). Successful cleavage was confirmed by SDS-PAGE and western blotting (see Fig. 4). 
Metal Chelate (Ni) Affinity Chromatography II. A I cm x 15cm Chelating Sepharose (Ni) Fast Flow column was prepared and 
equilibrated as described above. The digested protein was loaded and the column washed with 35mL of 2M urea, 0.02M Na2HP04, 
0.3M NaCI, 0.005M imidazole, pH 8.0 buffer. The column was further developed with 35mL steps ofO.125M, 0.250M, 0.325M, and 
0.5M imidazole in identical base buffer (2M urea, 0.02M Na2HP04, 0.3M NaCI, pH 8.0). Step fractions were collected and analyzed 
by SDS-PAGE and western blotting (see Fig. 5 and Fig. 6). 
SDS-PAGE. SDS-PAGE (12% acrylamide) was performed according to established protocol.48 
Western Blotting. 12% acrylamide SDS-PAGE gels were blotted onto nitrocellulose membrane (0.45Ilm pore size, Bio-Rad) pre-
wetted in 25mM Tris, 250mM Glycine, 15% (v/v) methanol transfer buffer by the filter paper sandwich method using a Trans-Blot SD 
Semi-Dry Electrophoretic Transfer Cell (Bio-Rad) for 15 minutes at 15V. The blotted membrane was blocked in 50mL of7.5% non-
fat milk in PBS for 30-60 min. 50mL of fresh 7.5% non-fat milk in PBS was added and the membrane was probed with a 1:2000 
dilution of murine Monoclonal Anti-polyHistidine-Peroxidase (Sigma A 7058-1 VL) and incubated for 30-60 min. The blot was then 
washed three times with 30-50mL 0.1 % (w/v) Tween 20 in PBS. HRP-conjugated antibody was detected using 4-chloro-l-naphthol. 
Results 
Rosetta cells were chosen for VNCD expression due to the presence of the pRARE plasmid, which encodes 
tRNAs for mammalian co dons that are seldom present in other E. coli celllines.49 VNCD was also expressed as 
a His-tagged SUMO fusion protein to enhance 
primary expression and solubility (see Fig. 1).50 
Unfortunately, the SUMO fusion alone was unable to 
overcome the inherent aggregative properties of the 
central domain; thus, the presence of urea was 
required throughout the purification process. 
Immediately following cell lysis and centrifugation, 
the cell lysate was clarified with Celpure 1000 and 
subjected to DEAE chromatography (see Fig. 2) to 
minimize incidental proteolysis. The dominant eluting 
DEAE peak was collected, pooled, and subjected to 
metal chelate (Ni) affinity chromatography to provide 
separation based on the poly-His tag present on the 
SUMO portion of the VNCD-SUMO fusion (see Fig. 
3). 
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Fig. 3. Nickel column elution profile (O.005M-O.30M 
imidazole gradient). Pooled fractions (11-21) are indicated. 
Following metal chelate (Ni) affinity purification, the pooled eluate was subjected to proteolytic cleavage of the 
SUMO domain from VNCD by the addition of SUMO Protease 1. Butt et at. had previously shown SUMO 
Protease 1 to be active at urea concentrations similar to those used in this work. 51 Successful cleavage was 
confirmed by the generation of three distinct bands post-digestion (SDS-PAGE, see Fig. 4). The lowest of these 
bands was western positive with murine apoly-His, while the upper two bands were western positive with 
Bunny-12 (polyclonal avitronectin). The bottom band is proposed to be the cleaved SUMO product; the top 
band, fully intact VNCD (~20523Da); and the middle band, VNCD cleaved incidentally by unknown 
protease(s) during purification. The SUMO cleavage product and SUMO protease were removed via a second 
round of metal chelate (Ni) affinity chromatography with an imidizole step gradient. This final purification step 
was confirmed by SDS-PAGE (see Fig. 5) and western blotting (apoly-His, see Fig. 6). 
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Fig. 4. Comparison of samples pre- and post-SUMO Protease I digest. Shown are a 12% acrylamide gel (samples stained with 
Coomassie Blue R-250, left), a western blot probed with murine apoly-His conjugated to HRP (center), and a western blot probed 
with Bunny-12 (polyclonal avitronectin, right). 
4 
O.OOSM 
• IMWiSh FT 
O.12SM 
1M Step 
O.2S0M 
J].1 Step 
0.375M 
1M Step 
0.500M 
IMStep 
-. 
4/812008 
12% SDS Page 
Coomassie . 
R250 
Fig. 5. 12% acrylamide gel of samples (stained with Coomassie Blue R-250) post-metal chelate (Ni) affinity chromatography 
(imidizole steps). The indicated band represents the cleaved SUMO product and SUMO protease, which both contain a poly-His 
tag. 
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Fig. 6. Western blot of samples post-metal chelate (Ni) affinity chromatography probed with murine apoly-His conjugated to 
HRP. The western positive band in the O.125M 1M Step lane represents the cleaved SUMO product and SUMO protease, which 
both contain a poly-His tag. 
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Discussion 
Following the second round of metal chelate (Ni) affinity chromatography, reversed phase HPLC allowed for 
the resolution of the two remaining VNCD bands (data not shown). Characterization of these purified samples 
via MALDI-TOF mass spectrometry necessitated the removal of urea from the sample buffer; thus, attempts at 
characterization were unsuccessful due to the self-aggregative properties of VNCD in the absence of urea. Of 
note is the reversibility of VNCD aggregation: The removal of urea promotes aggregation, while its 
reintroduction effects resolubilization (data not shown). Future experiments might entail VNCD expression in a 
eukaryotic system in order to achieve relevant post-translational modifications, as normal glycosylation has 
been shown to enhance vitronectin solubility.52 
Ultimately, the expression ofVNCD as a VNCD-SUMO fusion was not sufficiently able to overcome VNCD ~­
propeller-mediated oligomerization for the production of soluble monomers. However, it is the opinion of the 
author that although the purified product is largely unsuitable for biochemical assays/analyses due to its 
propensity for self-aggregation at high protein concentrations, certain low-concentration assays/analyses may be 
feasible since self-aggregation at low protein concentrations could be negligible. 
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